| Symptom . | Rhinovirus Only . | Rhinovirus Codetection . | Other Respiratory Viruses . |
|---|---|---|---|
| Total No. of Encounters | 986 | 80 | 503 |
| No. of unique participants | 647 | 66 | 410 |
| Asymptomatic | 445 (68.8) | 37 (56.1) | 190(46.3) |
| Symptomatic | 202 (31.2) | 29 (43.9) | 220 (53.7) |
| Runny nose or congestion | 155 (76.7) | 22 (75.9) | 177 (80.5) |
| Cough | 122 (60.4) | 23 (79.3) | 156 (70.9) |
| Sore throat | 80 (39.6) | 9 (31.0) | 99 (45.0) |
| Headaches | 75 (37.1) | 6 (20.7) | 76 (34.6) |
| Myalgias | 67 (33.2) | 7 (24.1) | 90 (40.9) |
| Fatigue | 62 (30.7) | 12 (41.4) | 90 (40.9) |
| Nausea or vomiting | 54 (26.7) | 9 (31.0) | 65 (29.6) |
| Chills | 45 (22.3) | 4 (13.8) | 57 (25.9) |
| Sweats | 38 (18.8) | 5 (17.2) | 53 (24.1) |
| Subjective fevers | 37 (18.3) | 9 (31.0) | 75 (34.1) |
| Shortness of breath | 37 (18.3) | 4 (13.8) | 53 (24.1) |
| Diarrhea | 22 (10.9) | 6 (20.7) | 39 (17.7) |
| Ear pain or discharge | 20 (9.9) | 1 (3.5) | 12 (5.5) |
| Rash | 8 (4.0) | 1 (3.5) | 12 (5.5) |
| Loss of taste or smellb | n = 160, 3 (1.9) | n = 26, 0 | n = 160, 2 (1.3) |
| Influenza-like illnessc | 35 (17.3) | 7 (24.1) | 68 (30.9) |
| COVID-19–like illnessd | 32 (15.8) | 6 (20.7) | 66 (30.0) |
| Fulfill both influenza-like illness and COVID-19-like illness criteria | 32 (15.8) | 6 (20.7) | 64 (29.1) |
| Symptom . | Rhinovirus Only . | Rhinovirus Codetection . | Other Respiratory Viruses . |
|---|---|---|---|
| Total No. of Encounters | 986 | 80 | 503 |
| No. of unique participants | 647 | 66 | 410 |
| Asymptomatic | 445 (68.8) | 37 (56.1) | 190(46.3) |
| Symptomatic | 202 (31.2) | 29 (43.9) | 220 (53.7) |
| Runny nose or congestion | 155 (76.7) | 22 (75.9) | 177 (80.5) |
| Cough | 122 (60.4) | 23 (79.3) | 156 (70.9) |
| Sore throat | 80 (39.6) | 9 (31.0) | 99 (45.0) |
| Headaches | 75 (37.1) | 6 (20.7) | 76 (34.6) |
| Myalgias | 67 (33.2) | 7 (24.1) | 90 (40.9) |
| Fatigue | 62 (30.7) | 12 (41.4) | 90 (40.9) |
| Nausea or vomiting | 54 (26.7) | 9 (31.0) | 65 (29.6) |
| Chills | 45 (22.3) | 4 (13.8) | 57 (25.9) |
| Sweats | 38 (18.8) | 5 (17.2) | 53 (24.1) |
| Subjective fevers | 37 (18.3) | 9 (31.0) | 75 (34.1) |
| Shortness of breath | 37 (18.3) | 4 (13.8) | 53 (24.1) |
| Diarrhea | 22 (10.9) | 6 (20.7) | 39 (17.7) |
| Ear pain or discharge | 20 (9.9) | 1 (3.5) | 12 (5.5) |
| Rash | 8 (4.0) | 1 (3.5) | 12 (5.5) |
| Loss of taste or smellb | n = 160, 3 (1.9) | n = 26, 0 | n = 160, 2 (1.3) |
| Influenza-like illnessc | 35 (17.3) | 7 (24.1) | 68 (30.9) |
| COVID-19–like illnessd | 32 (15.8) | 6 (20.7) | 66 (30.0) |
| Fulfill both influenza-like illness and COVID-19-like illness criteria | 32 (15.8) | 6 (20.7) | 64 (29.1) |
Data are No. (%) except where indicated.
A symptomatic encounter was defined as a study encounter in which the participant reported any new or worsening symptom on the enrollment questionnaire and was not limited to symptoms required for enrollment; an asymptomatic encounter was defined as a study encounter in which the participant did not report any new or worsening symptoms on the enrollment questionnaire.
Loss of taste or smell was added from 1 April 2020 onward. n is the number of people who were asked this question and proportion is out of total N.
Influenza-like illness is defined as the presence of fever and cough or sore throat.
COVID-19-like illness is defined as the presence of fever and cough or shortness of breath.
| Symptom . | Rhinovirus Only . | Rhinovirus Codetection . | Other Respiratory Viruses . |
|---|---|---|---|
| Total No. of Encounters | 986 | 80 | 503 |
| No. of unique participants | 647 | 66 | 410 |
| Asymptomatic | 445 (68.8) | 37 (56.1) | 190(46.3) |
| Symptomatic | 202 (31.2) | 29 (43.9) | 220 (53.7) |
| Runny nose or congestion | 155 (76.7) | 22 (75.9) | 177 (80.5) |
| Cough | 122 (60.4) | 23 (79.3) | 156 (70.9) |
| Sore throat | 80 (39.6) | 9 (31.0) | 99 (45.0) |
| Headaches | 75 (37.1) | 6 (20.7) | 76 (34.6) |
| Myalgias | 67 (33.2) | 7 (24.1) | 90 (40.9) |
| Fatigue | 62 (30.7) | 12 (41.4) | 90 (40.9) |
| Nausea or vomiting | 54 (26.7) | 9 (31.0) | 65 (29.6) |
| Chills | 45 (22.3) | 4 (13.8) | 57 (25.9) |
| Sweats | 38 (18.8) | 5 (17.2) | 53 (24.1) |
| Subjective fevers | 37 (18.3) | 9 (31.0) | 75 (34.1) |
| Shortness of breath | 37 (18.3) | 4 (13.8) | 53 (24.1) |
| Diarrhea | 22 (10.9) | 6 (20.7) | 39 (17.7) |
| Ear pain or discharge | 20 (9.9) | 1 (3.5) | 12 (5.5) |
| Rash | 8 (4.0) | 1 (3.5) | 12 (5.5) |
| Loss of taste or smellb | n = 160, 3 (1.9) | n = 26, 0 | n = 160, 2 (1.3) |
| Influenza-like illnessc | 35 (17.3) | 7 (24.1) | 68 (30.9) |
| COVID-19–like illnessd | 32 (15.8) | 6 (20.7) | 66 (30.0) |
| Fulfill both influenza-like illness and COVID-19-like illness criteria | 32 (15.8) | 6 (20.7) | 64 (29.1) |
| Symptom . | Rhinovirus Only . | Rhinovirus Codetection . | Other Respiratory Viruses . |
|---|---|---|---|
| Total No. of Encounters | 986 | 80 | 503 |
| No. of unique participants | 647 | 66 | 410 |
| Asymptomatic | 445 (68.8) | 37 (56.1) | 190(46.3) |
| Symptomatic | 202 (31.2) | 29 (43.9) | 220 (53.7) |
| Runny nose or congestion | 155 (76.7) | 22 (75.9) | 177 (80.5) |
| Cough | 122 (60.4) | 23 (79.3) | 156 (70.9) |
| Sore throat | 80 (39.6) | 9 (31.0) | 99 (45.0) |
| Headaches | 75 (37.1) | 6 (20.7) | 76 (34.6) |
| Myalgias | 67 (33.2) | 7 (24.1) | 90 (40.9) |
| Fatigue | 62 (30.7) | 12 (41.4) | 90 (40.9) |
| Nausea or vomiting | 54 (26.7) | 9 (31.0) | 65 (29.6) |
| Chills | 45 (22.3) | 4 (13.8) | 57 (25.9) |
| Sweats | 38 (18.8) | 5 (17.2) | 53 (24.1) |
| Subjective fevers | 37 (18.3) | 9 (31.0) | 75 (34.1) |
| Shortness of breath | 37 (18.3) | 4 (13.8) | 53 (24.1) |
| Diarrhea | 22 (10.9) | 6 (20.7) | 39 (17.7) |
| Ear pain or discharge | 20 (9.9) | 1 (3.5) | 12 (5.5) |
| Rash | 8 (4.0) | 1 (3.5) | 12 (5.5) |
| Loss of taste or smellb | n = 160, 3 (1.9) | n = 26, 0 | n = 160, 2 (1.3) |
| Influenza-like illnessc | 35 (17.3) | 7 (24.1) | 68 (30.9) |
| COVID-19–like illnessd | 32 (15.8) | 6 (20.7) | 66 (30.0) |
| Fulfill both influenza-like illness and COVID-19-like illness criteria | 32 (15.8) | 6 (20.7) | 64 (29.1) |
Data are No. (%) except where indicated.
A symptomatic encounter was defined as a study encounter in which the participant reported any new or worsening symptom on the enrollment questionnaire and was not limited to symptoms required for enrollment; an asymptomatic encounter was defined as a study encounter in which the participant did not report any new or worsening symptoms on the enrollment questionnaire.
Loss of taste or smell was added from 1 April 2020 onward. n is the number of people who were asked this question and proportion is out of total N.
Influenza-like illness is defined as the presence of fever and cough or sore throat.
COVID-19-like illness is defined as the presence of fever and cough or shortness of breath.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
